Global Myelodysplastic Syndrome Market 2015-2019 - Product Image

Global Myelodysplastic Syndrome Market 2015-2019

  • ID: 3608927
  • Report
  • Region: Global
  • 81 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Acceleron Pharma
  • Astellas
  • BioLineRx
  • CTI BioPharma
  • GlaxoSmithKline
  • Mirati Therapeutics
  • MORE
About Myelodysplastic Syndrome

Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with myelodysplastic syndrome. The disease is age-related, mostly affecting people aged 60 and above. Smoking, exposure to radiation, contact with chemicals such as benzene, genetic mutations, and chemotherapy can cause myelodysplastic syndrome.

The analysts forecast the global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.

Covered in this report
The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used for treating myelodysplastic syndrome.
The report describes the market by region:
- Americas: The US, Canada, Mexico, and Brazil
- EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
- APAC: Japan, China, Australia, Singapore, South Korea, and India

The report, Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Celgene
- Novartis
- Otsuka

Other prominent vendors
- Acceleron Pharma
- Amgen
- Astellas
- Astex
- Actinium Pharmaceuticals
- Bellicum Pharmaceuticals
- BioLineRx
- Celator Pharmaceuticals
- Cornerstone Pharmaceuticals
- CTI BioPharma
- Eli Lilly
- Gamida Cell
- GlaxoSmithKline
- KaloBios Pharmaceuticals
- Kiadis Pharma
- Mirati Therapeutics
- Onconova Therapeutics
- Strategia Therapeutics
- Sumitomo Dainippon Pharma
- Sunesis Pharmaceuticals
- Targazyme
- TetraLogic Pharmaceuticals

Market drivers
- Rise in aging population
- For a full, detailed list, view the full report

Market challenges
- Use of off-label drugs
- For a full, detailed list, view the full report

Market trends
- Rise in public awareness
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acceleron Pharma
  • Astellas
  • BioLineRx
  • CTI BioPharma
  • GlaxoSmithKline
  • Mirati Therapeutics
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Product profile
  • REVLIMID
  • VIDAZA
  • Dacogen
  • Glivec/Gleevec
PART 04: Market research methodology
  • Research methodology
  • Economic indicators
PART 05: Introduction
  • Key market highlights
PART 06: Disease overview
  • Understanding the disease
  • Risk factors
  • Signs and symptoms
  • Pathophysiology
  • Types
  • Diagnosis
  • Epidemiology
  • Treatment
PART 07: Pipeline portfolio
  • Information on pipeline candidates
PART 08: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 09: Market segmentation by drug class
  • Alkylating agents
  • Cytotoxic antibiotics
  • Topoisomerase inhibitors
  • Others
PART 10: Market segmentation by route of administration
  • Oral
  • Parenteral
PART 11: Geographical Segmentation
  • Myelodysplastic syndrome market in EMEA
  • Myelodysplastic syndrome market in APAC
PART 12: Market drivers
  • Rise in aging population
  • Unmet medical needs
  • Use of diagnostic tools
PART 13: Impact of drivers

PART 14: Market challenges
  • Use of off-label drugs
  • Adverse effects of drugs
  • High cost of drugs
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Rise in public awareness
  • Patient assistance programs
  • Increase in R&D
  • Intense competition
PART 17: Vendor landscape
  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors
PART 18: Key vendor analysis
  • Celgene
  • Novartis
  • Otsuka Holdings
PART 19: Appendix
  • List of abbreviations
PART 20: About the Author

Exhibit 01: Product offerings
Exhibit 02: Myelodysplastic syndrome: Risk factors
Exhibit 03: Myelodysplastic syndrome: Signs and symptoms
Exhibit 04: History of myelodysplastic syndrome classification system
Exhibit 05: FAB classification system: Types of myelodysplastic syndrome
Exhibit 06: WHO classification system: Types of myelodysplastic syndrome
Exhibit 07: IPSS classification: Factors and score
Exhibit 08: IPSS-R classification: Cytogenetic score
Exhibit 09: IPSS-R classification: Score values
Exhibit 10: IPSS-R classification: Risk categories and scores
Exhibit 11: Diagnostic tests for myelodysplastic syndrome
Exhibit 12: Myelodysplastic syndrome: Global incidence based on age 2007-2011 (years)
Exhibit 13: Myelodysplastic syndrome: Incidence in US by race 2007-2011
Exhibit 14: Treatment options for myelodysplastic syndrome
Exhibit 15: Chemotherapeutic agents
Exhibit 16: Immunotherapy drugs
Exhibit 17: Supportive therapy for myelodysplastic syndrome
Exhibit 18: Drugs that received orphan designation for treatment of myelodysplastic syndrome
Exhibit 19: Myelodysplastic syndrome: Drug pipeline
Exhibit 20: Global myelodysplastic syndrome market ($ millions)
Exhibit 21: Five forces analysis
Exhibit 22: Global myelodysplastic syndrome market segmentation by drug class
Exhibit 23: Global myelodysplastic syndrome market segmentation by route of administration
Exhibit 24: Global myelodysplastic syndrome market segmentation by geography 2014
Exhibit 25: Myelodysplastic syndrome market in Americas 2014-2019 ($ millions)
Exhibit 26: Myelodysplastic syndrome market in EMEA 2014-2019 ($ millions)
Exhibit 27: Myelodysplastic syndrome market in APAC 2014-2019 ($ millions)
Exhibit 28: Global myelodysplastic syndrome market segmentation by geography 2014-2019 ($ millions)
Exhibit 29: Impact of drivers
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Ranking of leading companies
Exhibit 32: Celgene: YoY growth and revenue of VIDAZA 2012-2014 ($ millions)
Exhibit 33: Celgene: YoY growth and revenue of REVLIMID 2012-2014 ($ billions)
Exhibit 34: Celgene: Key takeaways
Exhibit 35: Otsuka Holdings: Key takeaways
Exhibit 36: Novartis: Key takeaways
Exhibit 37: Celgene: Product segmentation by revenue 2014
Exhibit 38: Celgene: Product segmentation by revenue 2013 and 2014
Exhibit 39: Celgene: Geographical segmentation by revenue 2014
Exhibit 40: Novartis: Business segmentation by revenue 2014
Exhibit 41: Novartis: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 42: Novartis: Geographical segmentation by revenue 2014
Exhibit 43: Otsuka Holdings: Business segmentation by revenue 2014
Exhibit 44: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 45: Otsuka Holdings: Geographical segmentation by revenue 2014
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acceleron Pharma
  • Astellas
  • BioLineRx
  • CTI BioPharma
  • GlaxoSmithKline
  • Mirati Therapeutics
  • MORE
New Report Released: – Global Myelodysplastic Syndrome Market 2015-2019

The author of the report recognizes the following companies as the key players in the Global Myelodysplastic Syndrome Market: Celgene, Novartis and Otsuka

Other Prominent Vendors in the market are: Acceleron Pharma, Amgen, Astellas, Astex , Actinium Pharmaceuticals, Bellicum Pharmaceuticals, BioLineRx, Celator Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Eli-lilly, Gamida Cell , GlaxoSmithKline, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Onconova Therapeutics, Strategia Therapeutics, Sumitomo Dainippon Pharma , Sunesis Pharmaceuticals, Targazyme, and TetraLogic Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “Government organizations and pharmaceutical companies are conducting awareness programs to spread knowledge about the disease and associated drugs. In addition, they are also providing patient assistance programs to give low-income people with myelodysplastic syndrome access to these drugs. These two factors will surge the number of people availing treatment services, increasing the sales and consumption of drugs.”

According to the report, the immune system of an individual deteriorates as aging progresses. For this reason, people aged 60 and above are more susceptible to this disease. A surge in the population of this age group will increase the need for treatment drugs, positively influencing the latter's sales and revenue.

Further, the report states that the high cost of drugs used for treating myelodysplastic syndrome can deter people from consuming them.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Celgene
- Novartis
- Otsuka
- Acceleron Pharma
- Amgen
- Astellas
- Astex
- Actinium Pharmaceuticals
- Bellicum Pharmaceuticals
- BioLineRx
- Celator Pharmaceuticals
- Cornerstone Pharmaceuticals
- CTI BioPharma
- Eli-lilly
- Gamida Cell
- GlaxoSmithKline
- KaloBios Pharmaceuticals
- Kiadis Pharma
- Mirati Therapeutics
- Onconova Therapeutics
- Strategia Therapeutics
- Sumitomo Dainippon Pharma
- Sunesis Pharmaceuticals
- Targazyme
- TetraLogic Pharmaceuticals.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll